Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by gudisgoodon Mar 01, 2019 11:31am
75 Views
Post# 29428945

RE:RE:RE:RE:Goodman responds to letter

RE:RE:RE:RE:Goodman responds to letter
porksniffer wrote:
I think some context is in order because this is being spun to suit Mr. Goodman's false narrative.


Every single shareholder who bought exactly 3 years ago and still holds is sitting on a return of about........2%.

Everyone who bought exactly 2 years ago (ME!) who is still holding is DOWN anywhere from 23-30%.

Anyone who bought the last bought deal 2 years ago, the biggest one to date is DOWN 25%
 


Goodman cannot change market conditions. He can only do what's best at any given moment.

It's not Goodman's fault that the stock price is what it is (the market essentially gives the company zero "Goodman premium"). It's not Goodman's fault that opportunities within the pharma sector are running low at the moment.

Would you prefer that he just started investing recklessly instead of being disciplined?

Finally, shareholder value can be created without the stock price reacting to it instantly. The fact that the stock price has failed to improve (and even come down) within the past couple of years certainly doesn't mean that the company hasn't created shareholder value within that time. I would argue that the company has never been better positioned for the future.
Bullboard Posts